# An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

> **NCT03840512** · PHASE2 · UNKNOWN · sponsor: **Kalytera Therapeutics Israel, Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Prevention aGVHD

## Interventions

- **DRUG:** CBD

## Key facts

- **NCT ID:** NCT03840512
- **Lead sponsor:** Kalytera Therapeutics Israel, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-12
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840512, "An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03840512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*